Click for best price
Postpemic Era Cancer Genome Sequencing Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
(Post-pandemic Era)-Global Cancer Genome Sequencing Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Cancer Genome Sequencing industry at home and abroad, estimate the overall market scale of the Cancer Genome Sequencing industry and the market share of major countries, Cancer Genome Sequencing industry, and study and judge the downstream market demand of Cancer Genome Sequencing through systematic research, Analyze the competition pattern of Cancer Genome Sequencing, so as to help solve the pain points of various stakeholders in Cancer Genome Sequencing industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Cancer Genome Sequencing Market by Research Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Cancer Genome Sequencing Market?
Agilent Technologies
GE Healthcare Life Sciences
Johnson & Johnson
LI-COR Biosciences
Abbott Laboratories
Beckman Coulter
Bayer
Hamilton Thorne Biosciences
Integrated DNA Technologies
Microchip Biotechnologies
Myriad Genetics
Commonwealth Biotechnologies
ZS Genetics
Pacific Biosciences
Major Type of Cancer Genome Sequencing Covered in Research report:
Second Generation
Third Generation
Application Segments Covered in Research Market
Treatment
Research
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Cancer Genome Sequencing Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
90 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Cancer Genome Sequencing Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Cancer Genome Sequencing Market by Value
2.2.1 Global Cancer Genome Sequencing Revenue by Type
2.2.2 Global Cancer Genome Sequencing Market by Value
2.3 Global Cancer Genome Sequencing Market by Sales
2.3.1 Global Cancer Genome Sequencing Sales by Type
2.3.2 Global Cancer Genome Sequencing Market by Sales
3. The Major Driver of Cancer Genome Sequencing Industry
3.1 Historical & Forecast Global Cancer Genome Sequencing Sales and Revenue (2018-2028)
3.2 Largest Application for Cancer Genome Sequencing (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Cancer Genome Sequencing Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Cancer Genome Sequencing Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Cancer Genome Sequencing Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Cancer Genome Sequencing Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Cancer Genome Sequencing Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Cancer Genome Sequencing Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Cancer Genome Sequencing Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Cancer Genome Sequencing Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Cancer Genome Sequencing Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Cancer Genome Sequencing Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Cancer Genome Sequencing Average Price Trend
13.1 Market Price for Each Type of Cancer Genome Sequencing in US (2018-2022)
13.2 Market Price for Each Type of Cancer Genome Sequencing in Europe (2018-2022)
13.3 Market Price for Each Type of Cancer Genome Sequencing in China (2018-2022)
13.4 Market Price for Each Type of Cancer Genome Sequencing in Japan (2018-2022)
13.5 Market Price for Each Type of Cancer Genome Sequencing in India (2018-2022)
13.6 Market Price for Each Type of Cancer Genome Sequencing in Korea (2018-2022)
13.7 Market Price for Each Type of Cancer Genome Sequencing in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Cancer Genome Sequencing in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Cancer Genome Sequencing Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Cancer Genome Sequencing
15. Cancer Genome Sequencing Competitive Landscape
15.1 Agilent Technologies
15.1.1 Agilent Technologies Company Profiles
15.1.2 Agilent Technologies Product Introduction
15.1.3 Agilent Technologies Cancer Genome Sequencing Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 GE Healthcare Life Sciences
15.2.1 GE Healthcare Life Sciences Company Profiles
15.2.2 GE Healthcare Life Sciences Product Introduction
15.2.3 GE Healthcare Life Sciences Cancer Genome Sequencing Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Johnson & Johnson
15.3.1 Johnson & Johnson Company Profiles
15.3.2 Johnson & Johnson Product Introduction
15.3.3 Johnson & Johnson Cancer Genome Sequencing Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 LI-COR Biosciences
15.4.1 LI-COR Biosciences Company Profiles
15.4.2 LI-COR Biosciences Product Introduction
15.4.3 LI-COR Biosciences Cancer Genome Sequencing Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Abbott Laboratories
15.5.1 Abbott Laboratories Company Profiles
15.5.2 Abbott Laboratories Product Introduction
15.5.3 Abbott Laboratories Cancer Genome Sequencing Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Beckman Coulter
15.6.1 Beckman Coulter Company Profiles
15.6.2 Beckman Coulter Product Introduction
15.6.3 Beckman Coulter Cancer Genome Sequencing Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Bayer
15.7.1 Bayer Company Profiles
15.7.2 Bayer Product Introduction
15.7.3 Bayer Cancer Genome Sequencing Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Hamilton Thorne Biosciences
15.8.1 Hamilton Thorne Biosciences Company Profiles
15.8.2 Hamilton Thorne Biosciences Product Introduction
15.8.3 Hamilton Thorne Biosciences Cancer Genome Sequencing Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 Integrated DNA Technologies
15.9.1 Integrated DNA Technologies Company Profiles
15.9.2 Integrated DNA Technologies Product Introduction
15.9.3 Integrated DNA Technologies Cancer Genome Sequencing Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 Microchip Biotechnologies
15.10.1 Microchip Biotechnologies Company Profiles
15.10.2 Microchip Biotechnologies Product Introduction
15.10.3 Microchip Biotechnologies Cancer Genome Sequencing Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
15.11 Myriad Genetics
15.12 Commonwealth Biotechnologies
15.13 ZS Genetics
15.14 Pacific Biosciences
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Cancer Genome Sequencing Industry (Volume)
Figure 2. Cancer Genome Sequencing Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Cancer Genome Sequencing Revenue in 2022
Figure 5. US Cancer Genome Sequencing Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Cancer Genome Sequencing Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Cancer Genome Sequencing Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Cancer Genome Sequencing Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Cancer Genome Sequencing Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Cancer Genome Sequencing Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Cancer Genome Sequencing Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Cancer Genome Sequencing Revenue, by Type (Million USD) (2018-2028)
Table 4. Cancer Genome Sequencing Sales, by Type (K Unit) (2018-2028)
Table 5. Cancer Genome Sequencing Sales (K Unit) by Application (2018-2028)
Table 6. Cancer Genome Sequencing Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Cancer Genome Sequencing Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Cancer Genome Sequencing Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Cancer Genome Sequencing Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Cancer Genome Sequencing Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Cancer Genome Sequencing Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Cancer Genome Sequencing Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Cancer Genome Sequencing Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Cancer Genome Sequencing Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Cancer Genome Sequencing in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Cancer Genome Sequencing in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Cancer Genome Sequencing in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Cancer Genome Sequencing in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Cancer Genome Sequencing in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Cancer Genome Sequencing in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Cancer Genome Sequencing in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Agilent Technologies Profiles
Table 61. Agilent Technologies Cancer Genome Sequencing Product Introduction
Table 62. Agilent Technologies Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Agilent Technologies Strategic initiatives
Table 64. GE Healthcare Life Sciences Profiles
Table 65. GE Healthcare Life Sciences Cancer Genome Sequencing Product Introduction
Table 66. GE Healthcare Life Sciences Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. GE Healthcare Life Sciences Strategic initiatives
Table 68. Johnson & Johnson Profiles
Table 69. Johnson & Johnson Cancer Genome Sequencing Product Introduction
Table 70. Johnson & Johnson Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Johnson & Johnson Strategic initiatives
Table 72. LI-COR Biosciences Profiles
Table 73. LI-COR Biosciences Cancer Genome Sequencing Product Introduction
Table 74. LI-COR Biosciences Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. LI-COR Biosciences Strategic initiatives
Table 76. Abbott Laboratories Profiles
Table 77. Abbott Laboratories Cancer Genome Sequencing Product Introduction
Table 78. Abbott Laboratories Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Abbott Laboratories Strategic initiatives
Table 80. Beckman Coulter Profiles
Table 81. Beckman Coulter Cancer Genome Sequencing Product Introduction
Table 82. Beckman Coulter Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Beckman Coulter Strategic initiatives
Table 84. Bayer Profiles
Table 85. Bayer Cancer Genome Sequencing Product Introduction
Table 86. Bayer Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Bayer Strategic initiatives
Table 88. Hamilton Thorne Biosciences Profiles
Table 89. Hamilton Thorne Biosciences Cancer Genome Sequencing Product Introduction
Table 90. Hamilton Thorne Biosciences Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Hamilton Thorne Biosciences Strategic initiatives
Table 92. Integrated DNA Technologies Profiles
Table 93. Integrated DNA Technologies Cancer Genome Sequencing Product Introduction
Table 94. Integrated DNA Technologies Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Integrated DNA Technologies Strategic initiatives
Table 97. Microchip Biotechnologies Profiles
Table 98. Microchip Biotechnologies Cancer Genome Sequencing Product Introduction
Table 99. Microchip Biotechnologies Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Microchip Biotechnologies Strategic initiatives
Table 101. Myriad Genetics Profiles
Table 102. Myriad Genetics Cancer Genome Sequencing Product Introduction
Table 103. Myriad Genetics Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. Myriad Genetics Strategic initiatives
Table 105. Commonwealth Biotechnologies Profiles
Table 106. Commonwealth Biotechnologies Cancer Genome Sequencing Product Introduction
Table 107. Commonwealth Biotechnologies Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 108. Commonwealth Biotechnologies Strategic initiatives
Table 109. ZS Genetics Profiles
Table 110. ZS Genetics Cancer Genome Sequencing Product Introduction
Table 111. ZS Genetics Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 112. ZS Genetics Strategic initiatives
Table 113. Pacific Biosciences Profiles
Table 114. Pacific Biosciences Cancer Genome Sequencing Product Introduction
Table 115. Pacific Biosciences Cancer Genome Sequencing Sales (Unit), Revenue (Million USD) (2018-2022)
Table 116. Pacific Biosciences Strategic initiatives
